Afficher la notice abrégée

dc.contributor.editorRaup-Konsavage, Wesley M.
dc.date.accessioned2023-07-14T14:24:24Z
dc.date.available2023-07-14T14:24:24Z
dc.date.issued2023
dc.identifierONIX_20230714_9783036575827_25
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/101326
dc.description.abstractCannabis has a history of medical use dating back millennia; however, the use of cannabis for medicinal purposes fell out of favor in the middle of the last century. There is currently a renewed interest in the potential medicinal value of this plant, as well as individual compounds produced by Cannabis (as well as synthetic analogs). Currently, nearly 50 countries permit the medical use of cannabis, and over a dozen other countries have legalized cannabis-based products (CBD, Sativex, Dronabinol, etc.) for medical use. While there exists a plethora of anecdotal reports indicating that cannabis can treat a variety of diseases, there is a limited amount of strong, evidence-based scientific data to support these claims. This Special Edition of Biomedicines, “Therapeutic Potential for Cannabis and Cannabinoids”, was dedicated to providing evidence for the medicinal value of cannabis to treat human illness and disease. Topics included, but were not limited to, preclinical animal models examining the efficacy of cannabis and cannabinoid derivatives on pain, anxiety, cancer, and other diseases; and cell and molecular models of cannabinoid pharmacokinetics, drug–drug interactions, and disease treatment. These studies are of great importance not only for progressing the cannabis field, but also for validating the use of cannabis and cannabinoids as therapeutics.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursingen_US
dc.subject.otheranti-microbial activity
dc.subject.otheranti-biofilm activity
dc.subject.otherCannabis sativa L.
dc.subject.otherendocannabinoids
dc.subject.othergut microbiota
dc.subject.otherpathogens
dc.subject.otherphytocannabinoids
dc.subject.othersynovial fibroblast
dc.subject.otherrheumatoid arthritis
dc.subject.othercannabis
dc.subject.othertetrahydrocannabinol
dc.subject.othercytokines
dc.subject.othercalcium
dc.subject.otherPBMC
dc.subject.othercannabinoid receptors
dc.subject.otherTRPA1
dc.subject.other2-hydroxy oleic acid
dc.subject.otheranandamide
dc.subject.otheranti Bcl2
dc.subject.otherendocannabinoid system
dc.subject.othermembrane lipid therapy
dc.subject.otherneuroblastoma
dc.subject.otherN-arachidonoylethanolamine
dc.subject.othercortisol
dc.subject.otherchronic pain
dc.subject.otherinjury
dc.subject.otherautism spectrum disorder
dc.subject.othercannabinoids
dc.subject.othercannabidiol
dc.subject.otherclinical trials
dc.subject.otherrandomized controlled
dc.subject.othersleep
dc.subject.otherchild psychiatry
dc.subject.otherdevelopmental disorders
dc.subject.otherrat
dc.subject.otherpost-traumatic stress disorder (PTSD)
dc.subject.otherURB597
dc.subject.othermGluR5
dc.subject.otherCB1 receptor
dc.subject.otherfatty acid amide hydrolase (FAAH)
dc.subject.otherβ-catenin
dc.subject.othercannabinoid
dc.subject.otherimmune
dc.subject.othermacrophage
dc.subject.otherelderly
dc.subject.otherinflammatory bowel disease
dc.subject.otherD9 tetrahydrocannabinol
dc.subject.othernitric oxide
dc.subject.otherepilepsy
dc.subject.otheranimal model
dc.subject.othercognitive dysfunction
dc.subject.otherzebrafish
dc.subject.other∆9-tetrahydrocannabinol
dc.subject.otherTHC
dc.subject.otherCBD
dc.subject.otherprefrontal cortex
dc.subject.otherstriatum
dc.subject.otherBDNF
dc.subject.otheraging
dc.subject.otherage-related diseases
dc.subject.otherneuropathic pain
dc.subject.otheranxiety
dc.subject.otherinhalation
dc.subject.otherHRQoL
dc.subject.otherphytochemistry
dc.subject.otherterpenes
dc.subject.othersynergy
dc.subject.otherentourage effect
dc.subject.otherbiosynthesis
dc.subject.otherHIV
dc.subject.othercannabidiol (CBD)
dc.subject.othertetrahydrocannabinol (THC)
dc.subject.otherchronic liver diseases
dc.subject.otherquality of life
dc.subject.otherpilot clinical trial
dc.subject.otherMMP-2
dc.subject.otherMMP-9
dc.subject.otherVSMC
dc.subject.otherH9c2 cells
dc.subject.otherglucose
dc.subject.othercell proliferation
dc.subject.otherapoptosis
dc.subject.othercardiovascular disease
dc.subject.otherFAAH inhibitors
dc.subject.otherMGL inhibitors
dc.subject.otherneonatal brain injury
dc.subject.otherhypoxia–ischemia
dc.subject.otherneuroprotection
dc.subject.otherneurogenesis
dc.subject.otherinflammation
dc.subject.otherbile acids
dc.subject.othertranscriptomics
dc.subject.otherestrogen deficiency
dc.subject.otherovariectomized mice
dc.subject.otherpostmenopause
dc.subject.othergut organoids
dc.subject.otherghrelin
dc.subject.otherGHSR signaling
dc.subject.otherlate adolescence
dc.subject.othermedical cannabis
dc.subject.otherpolypharmacy
dc.subject.othern/a
dc.titleTherapeutic Potential for Cannabis and Cannabinoids
dc.typebook
oapen.identifier.doi10.3390/books978-3-0365-7583-4
oapen.relation.isPublishedBy46cabcaa-dd94-4bfe-87b4-55023c1b36d0
oapen.relation.isbn9783036575827
oapen.relation.isbn9783036575834
oapen.pages424
oapen.place.publicationBasel


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/4.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/4.0/